• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Can Price Transparency Contribute to More Affordable Patient Access to Medicines?价格透明度能否有助于患者以更可承受的价格获得药品？
Pharmacoecon Open. 2017 Sep;1(3):145-147. doi: 10.1007/s41669-017-0028-1.
2
How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.定价与报销政策如何提高药品的可及性？从欧洲国家汲取的经验教训。
Appl Health Econ Health Policy. 2017 Jun;15(3):307-321. doi: 10.1007/s40258-016-0300-z.
3
How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.《跨太平洋伙伴关系协定如何损害 PHARMAC 并威胁新西兰平价药品的可及性和医疗公平性》
Health Policy. 2013 Oct;112(3):227-33. doi: 10.1016/j.healthpol.2013.07.021. Epub 2013 Aug 30.
4
Information system technologies' role in augmenting dermatologists' knowledge of prescription medication costs.信息系统技术在增强皮肤科医生对处方药成本了解方面的作用。
Int J Med Inform. 2015 Dec;84(12):1076-84. doi: 10.1016/j.ijmedinf.2015.06.009. Epub 2015 Jul 15.
5
Availability, Price and Affordability of Anticancer Medicines: Evidence from Two Cross-Sectional Surveys in the Jiangsu Province, China.抗癌药物的可及性、价格和可负担性：来自中国江苏省两项横断面调查的证据。
Int J Environ Res Public Health. 2019 Oct 3;16(19):3728. doi: 10.3390/ijerph16193728.
6
Price comparison of high-cost originator medicines in European countries.欧洲国家高成本原研药的价格比较。
Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):221-230. doi: 10.1080/14737167.2016.1223543. Epub 2016 Oct 11.
7
Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.医改后获得平价药品的机会：来自中国西部陕西省的两项横断面调查证据。
Lancet Glob Health. 2013 Oct;1(4):e227-37. doi: 10.1016/S2214-109X(13)70072-X. Epub 2013 Sep 24.
8
Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: a cluster-randomised controlled trial.诺华准入方案对肯尼亚非传染性疾病药物供应和价格的影响：一项集群随机对照试验。
Lancet Glob Health. 2019 Apr;7(4):e492-e502. doi: 10.1016/S2214-109X(18)30563-1. Epub 2019 Feb 21.
9
Access to essential cardiovascular medicines for children: a pilot study of availability, price and affordability in Nigeria.儿童基本心血管药物的可及性：尼日利亚可用性、价格和可负担性的试点研究。
Health Policy Plan. 2019 Dec 1;34(Supplement_3):iii20-iii26. doi: 10.1093/heapol/czz057.
10
[Risk sharing methods in middle income countries].[中等收入国家的风险分担方法]
Acta Pharm Hung. 2012;82(1):43-52.

引用本文的文献

1
On paper; in practice: measuring compliance with official pricing policies in a large field study of essential medicines in Indonesia.理论上；实践中：在印度尼西亚一项关于基本药物的大型实地研究中衡量对官方定价政策的遵守情况。
J Pharm Policy Pract. 2025 Jul 2;18(1):2521434. doi: 10.1080/20523211.2025.2521434. eCollection 2025.
2
Medication Recommendation, Counseling, and Pricing for Nasal Sprays in German Community Pharmacies: A Simulated Patient Investigation.德国社区药房鼻喷雾剂的用药建议、咨询及定价：一项模拟患者调查
Adv Respir Med. 2025 Jun 13;93(3):18. doi: 10.3390/arm93030018.
3
Unraveling elements of value-based pricing from a pharmaceutical industry's perspective: a scoping review.从制药行业视角剖析基于价值定价的要素：一项范围综述
Front Pharmacol. 2024 Jun 24;15:1298923. doi: 10.3389/fphar.2024.1298923. eCollection 2024.
4
Medicines prices in International (Geary-Khamis) Dollar. The comparison between regulated and deregulated markets.国际（Geary-Khamis）美元中的药品价格。管制市场与非管制市场的比较。
PLoS One. 2024 Jun 7;19(6):e0304400. doi: 10.1371/journal.pone.0304400. eCollection 2024.
5
Market Transparency in Medicine Pricing: Pathways to Fair Pricing.药品定价中的市场透明度：实现公平定价的途径
Pharmacoeconomics. 2024 Jun;42(6):611-614. doi: 10.1007/s40273-024-01390-y. Epub 2024 May 9.
6
Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices.四个西欧国家在市场独占期满前后的孤儿药价格：目录价格和购买价格的跨国比较。
Appl Health Econ Health Policy. 2023 Nov;21(6):905-914. doi: 10.1007/s40258-023-00832-6. Epub 2023 Sep 26.
7
Introduction of managed entry agreements in Korea: Problem, policy, and politics.韩国引入管理式准入协议：问题、政策与政治
Front Pharmacol. 2023 Apr 13;14:999220. doi: 10.3389/fphar.2023.999220. eCollection 2023.
8
Transparency of data on the value chain of medicines in Argentina, Brazil, and Colombia.阿根廷、巴西和哥伦比亚药品价值链数据的透明度。
Front Pharmacol. 2023 Jan 5;13:1063300. doi: 10.3389/fphar.2022.1063300. eCollection 2022.
9
Evidence on the effectiveness of policies promoting price transparency - A systematic review.关于促进价格透明度政策有效性的证据——系统评价。
Health Policy. 2023 Aug;134:104681. doi: 10.1016/j.healthpol.2022.11.002. Epub 2022 Nov 8.
10
How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries.我们如何优化用于报销目的的罕见病药物价值评估和评价？一项对欧洲国家的定性访谈研究。
Front Pharmacol. 2022 Jul 19;13:902150. doi: 10.3389/fphar.2022.902150. eCollection 2022.

本文引用的文献

1
Payers' experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia.付款方对药品保密价格折扣的体验：对北美、欧洲和澳大拉西亚公共及法定医疗系统的一项调查。
Health Policy. 2017 Apr;121(4):354-362. doi: 10.1016/j.healthpol.2017.02.002. Epub 2017 Feb 16.
2
How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.定价与报销政策如何提高药品的可及性？从欧洲国家汲取的经验教训。
Appl Health Econ Health Policy. 2017 Jun;15(3):307-321. doi: 10.1007/s40258-016-0300-z.
3
Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.30个国家丙型肝炎新药的价格、成本及可负担性：一项经济分析
PLoS Med. 2016 May 31;13(5):e1002032. doi: 10.1371/journal.pmed.1002032. eCollection 2016 May.
4
Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference.危机中的药品政策？PPRI会议确定的挑战与解决方案
J Pharm Policy Pract. 2016 Mar 15;9:9. doi: 10.1186/s40545-016-0056-8. eCollection 2016.
5
Actual costs of cancer drugs in 15 European countries.15个欧洲国家癌症药物的实际成本。
Lancet Oncol. 2016 Jan;17(1):18-20. doi: 10.1016/S1470-2045(15)00486-6. Epub 2015 Dec 4.
6
Differential pricing of new pharmaceuticals in lower income European countries.欧洲低收入国家新药品的差异化定价。
Expert Rev Pharmacoecon Outcomes Res. 2013 Dec;13(6):735-41. doi: 10.1586/14737167.2013.847367.
7
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.生命价值几何：西妥昔单抗、非小细胞肺癌与那4400亿美元的问题
J Natl Cancer Inst. 2009 Aug 5;101(15):1044-8. doi: 10.1093/jnci/djp177. Epub 2009 Jun 29.
8
The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s.价格管制对新药上市延迟的影响——来自20世纪90年代25个主要市场的证据。
Health Econ. 2005 Mar;14(3):269-92. doi: 10.1002/hec.931.

Can Price Transparency Contribute to More Affordable Patient Access to Medicines?

作者信息

Vogler Sabine, Paterson Kenneth R

机构信息

WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG/Austrian Public Health Institute), Vienna, Austria.

University of Glasgow, Glasgow, Scotland, UK.

出版信息

Pharmacoecon Open. 2017 Sep;1(3):145-147. doi: 10.1007/s41669-017-0028-1.

DOI:10.1007/s41669-017-0028-1
PMID:29441499
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5691843/
Abstract
摘要